Trials / Completed
CompletedNCT02095964
HDL-C in Cardiac Syndrome X
HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 710 (actual)
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital · Other Government
- Sex
- All
- Age
- 47 Years – 58 Years
- Healthy volunteers
- Accepted
Summary
High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver\[10\]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity\[11\]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk\[12-14\]. HDL-C also has anti- inflammatory and anti-oxidant activities\[15,16\]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils\[17,18\] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin\[15\]. In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).
Conditions
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-12-01
- Completion
- 2014-01-01
- First posted
- 2014-03-26
- Last updated
- 2014-03-26
Source: ClinicalTrials.gov record NCT02095964. Inclusion in this directory is not an endorsement.